Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$5.01+12.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · CPIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -56.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 19.0% |
Growth built into the price is above our model estimate.
The price assumes 75.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 12 industry peers · Company calendar date is not available
CPIX — litigation filed
Dated 2026-10-26
Other Events . On October 26, 2026, the Company provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with DMD. The Company announced plans to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration (the “FDA”) for ifetroban as a treatment for the cardiomyopathy associated with DMD. The decision to file the NDA for a Traditional Approval follows a pre-NDA meeting held this fall with the FDA. The p…
Why it matters: Cumberland is now a development-stage company. It reported a $3.1 million quarterly loss from continuing operations. Cash use may affect how long it can fund its programs.
Worry ifA quarterly report shows cash use from ongoing work above $3.1 million, or cash below about $4 million on June 30. It names no funding source.
Less concerning ifQuarterly cash use is at or below $3.1 million and reported cash remains at or above about $4 million.
Why it matters: These results are the stated next milestone for this ifetroban program. A clear positive result would support further study.
Supportive ifCumberland reports Phase 2 results that meet the study's goals. The results support more development.
Worry ifCumberland says the study missed its goals or gives no results update in its next company update.
Why it matters: Cumberland plans to seek traditional FDA approval for ifetroban in DMD heart disease. FDA acceptance would move this program into review.
Supportive ifThe FDA accepts Cumberland's NDA for ifetroban to treat DMD-related heart disease. It sets a review date.
Worry ifCumberland delays the filing, or the FDA refuses to accept the NDA for review.
Why it matters: The company reported better heart measures and matching blood markers in its Phase 2 study. FDA feedback will help show what evidence comes next.
Watch forCumberland reports that FDA feedback supports its planned NDA path without asking for a new clinical trial.
Also watch forCumberland reports that the FDA requires a new clinical trial or does not support the planned NDA path.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$296 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $785 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,295 loss on $10,000 · 52.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.